Targeting the mucosa: Genetically engineered vaccines and mucosal immune responses

Genes and Immunity

Volumn 1, Issue 5, 2000, Pages 308-315

  Stevceva, L ^a   Abimiku, A G ^b   Franchini, G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

CTL; IgA; Mucosa; Naked DNA; Vaccine

Indexed keywords

DNA VACCINE;

ANIMAL; ANTIGEN PRESENTATION; BACTERIUM; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; MUCOSAL IMMUNITY; REVIEW; VIRUS;

ANIMALS; ANTIGEN PRESENTATION; BACTERIA; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; VACCINES, DNA; VIRUSES;

EID: 0034208632     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363680     Document Type: Review

References (75)

1. Brandtzaeg P, Baekkevold ES, Farstad IN et al. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol Today 1999; 20: 141-151.
2. Persson CG, Erjefalt JS, Greiff L et al. Contribution of plasma-derived molecules to mucosal immune defence, disease and repair in the airways. Scand J Immunol 1998; 47: 302-13.
3. Brandtzaeg P. Mucosal immunity in the female genital tract. J Reprod Immunol 1997; 36: 23-50.
4. Mascola J, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-210.
5. Mascola J, Lewis MG, Stiegler G et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-1018.
6. Baba T, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 200-206.
7. Robert-Guroff, M. IgG surfaces as an important component in mucosal protection. Nat Med 2000; 6: 129-130.
8. Kantele A, Zivny J, Hakkinen M et al. Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. J Immunol 1999; 162: 5173-5177.
9. Noll A, Bucheler N, Bohn E et al. DNA immunization confers systemic, but not mucosal, protection against enteroinvasive bacteria. Eur J Immunol 1999; 29: 986-996.
10. Okada E, Sasaki S, Ishii N et al. Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997; 159: 3638-3647.
11. Chen SC, Jones DH, Fynan EF. et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998; 72: 5757-5761.
12. Brandtzaeg P, Farstad IN, Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today 1999; 20: 267-277.
13. Mestecky J, Fultz PN. Mucosal immune system of the human genital tract. J Infect Dis 1999; 179 (Suppl 3): S470-S474.
14. Crowley-Nowick PA, Bell MC, Brockwell R. et al. Rectal immunization for induction of specific antibody in the genital tract of women. J Clin Immunol 1997; 17: 370-379.
15. Wang B, Dang K, Agadjanyan MG, et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine 1997; 15: 821-825.
16. Livingston JB, Lu S, Robinson H, Anderson DJ et al. Immunization of the female genital tract with a DNA-based vaccine. Infect Immun 1998; 66: 322-329.
17. Westermann J, Bode U, Pabst R et al. Migration of so-called naive and memory T lymphocytes from blood to lymph in the rat. The influence of IFN-gamma on the circulation pattern. J Immunol 1994; 152: 1744-1750.
18. Westermann J, Pabst R. How organ-specific is the migration of 'naive' and 'memory' T cells? [see comments]. Immunol Today 1996; 17: 278-282.
19. Drayson MT. The entry of lymphocytes into stimulated lymph nodes. The site of selection of alloantigen-specific cells. Transplantation 1986; 41: 745-751.
20. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90: 11478-11482.
21. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2: 1122-1128.
22. Ulmer JB, Deck RR, Dewitt CM, Donnhly JI, Liu MA. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996; 89: 59-67.
23. Raz E, Tighe, H, Sato Y et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996: 93: 5141-5145.
24. Martinez X, Brandt C, Saddallah F et al. DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life. Proc Natl Acad Sci USA 1997; 94: 8726-6731.
25. Haensler J, Verdelet C, Sanchez V et al Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999; 17: 628-638.
26. Raz E, Carson DA, Parker SE et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994; 91: 9519-9523.
27. Ishida T, Mizushima Si, Azuma S, Kobayashi N et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996; 271: 28745-28748.
28. Charo J, Ciupitu AM, Le Chevalier De Preville A et al. A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene. J Immunol 1999; 163: 5913-5919.
29. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-391.
30. Bona CA, Casares S, Brumeanu TD. Towards development of T-cell vaccines. Immunol Today 1998; 19: 126-133.
31. Roscoe DE, Holste WC, Sorhage FE et al. Efficacy of an oral vaccinia-rabies glycoprotein recombinant vaccine in controlling epidemic raccoon rabies in New Jersey. J Wildl Dis 1998; 34: 752-763.
32. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998; 72: 10180-10188.
33. Hanke T, Samuel RV, Blanchard TJ et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999; 73: 7524-7532.
34. Caver TE, Lockey TD, Srinivas RV, Webster RG, Hurwitz JL. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 1999; 17: 1567-1572.
35. Chatterjee S, Qin H, Manna S, Tripathi PK, Recombinant vaccinia virus expressing GM-CSF as tumor vaccine. Anticancer Res 1999; 19: 2869-2873.
36. Valmori D, Levy F, Miconnet I et al. Induction of potent anti-tumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 2000; 164: 1125-1131.
37. Paoletti E. Poxvirus recombinant vaccines. Ann NY Acad Sci 1990; 590: 309-325.
38. Franchini G, Bosch ML. Genetic relatedness of the human immunodeficiency viruses type 1 and 2 (HIV-1, HIV-2) and the simian immunodeficiency virus (SIV). Ann NY Acad Sci 1989; 544: 81-87.
39. Robert-Guroff M, Aldrich K, Muldoon R et al. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. J Virol 1992; 66: 3602-3608.
40. Abimiku A, Franchini G, Tatrtaglia J et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med 1995; 1: 321-329.
41. Graham BS, McElrath MJ, Connor RI et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis 1998; 177: 310-319.
42. Chengalvala M, Lubeck MD, Davis AR et al. Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs. Vaccine 1991; 9: 485-490.
43. Schneider M, Graham FL, Prevec L. Expression of the glycoprotein of vesicular stomatitis virus by infectious adenovirus vectors. J Gen Virol 1989; 70: 417-427.
44. Lubeck MD, Natuk R, Myagkikh M et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997; 3: 651-658.
45. Donson A, Foreman NK. Adenovirus mediated gene therapy in a glioblastoma vaccine model; specific antitumor immunity and abrogation of immunosuppression. J Neurooncol 1998; 40: 205-214.
46. Xiang Z, Ertl HC. Induction of mucosal immunity with a replication-defective adenoviral recombinant. Vaccine 1999; 17: 2003-2008.
47. Ochsenbein A, Karrer U, Klenerman P. A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proc Natl Acad Sci USA 1999; 96: 9293-9298.
48. Letvin NL, Daniel MD, Sehgal PK et al. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 1985; 230: 71-73.
49. Crotty S, Lohman BL, Lu FX, Tang S, Miller CJ, Andino R. Mucosal immunization of cynomolgus macaques with two sero-types of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J Virol 1999; 73: 9485-9495.
50. Todryk S, McLean C, Ali S et al. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum Gene Ther 1999; 10: 2757-2768.
51. Leitner W, Ying H, Driver DA, Dubensky TW, Restflo NP. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 2000; 60: 51-55.
52. Kremer L, Dupre L, Riveau G, Capron A, Locht C. Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing glutathione S-transferase from Schistosoma haematobium. Infect Immun 1998; 66: 5669-5676.
53. Lagranderie M, Winter N, Balazuc AM, Gicquel B, Gheorghiu M. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res Hum Retroviruses 1998; 14: 1625-1633.
54. Lagranderie M, Balazuc AM, Gicquel B, Gheorghiu M. Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice. J Virol 1997; 71: 2303-2309.
55. Winter N, Lagranderie M, Rauzier J et al. Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene 1991; 109: 47-54.
56. Kameoka M, Nishino Y, Matsuo K et al. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine 1994; 12: 153-158.
57. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995; 270: 299-302.
58. Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol 1999; 162: 1603-1610.
59. Kaufmann S. Fundamental Immunology. Paul WE (ed). Lippincott-Raven: 1998, pp 1335-1371.
60. Darji A, Guzman CA, Gerstel B et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997; 91: 765-775.
61. Paglia P, Medina E, Arioli J, Guzman CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92: 3172-3176.
62. Pasetti MF, Anderson RJ, Noriega FR, Levine MM, Sztein MB. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol 1999; 92: 76-89.
63. Catmull J, Wilson ME, Kirchhoff LV, Metwali A, Donelson JE. Induction of specific cell-mediated immunity in mice by oral immunization with Salmonella expressing Onchocerca volvulus glutathione S-transferase. Vaccine 1999; 17: 31-39.
64. Dietrich G, Bubert A, Gentschev I et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes [see comments]. Nat Biotechnol 1998; 16: 181-185.
65. Maassen C, Laman JD, den Bak-Glashouwer MJ et al. Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Vaccine 1999; 17: 2117-2128.
66. Sin JI, Kim JJ, Boyer JD, Ciccarelli RB, Higgins TJ, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a ThI phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999; 73: 501-509.
67. Sin JI, Kim JJ, Arnold RL, Shroff KE et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 1999; 162: 2912-2921.
68. Tartaglia J, Franchini G, Robert-Guroff M et al. Highly attenuated poxvirus vector strains, NYVAC and ALVAC, in retrovirus vaccine development. In: HuitiËme Colloque Des Cent Gardes -1993 (Proceedings). Robert O (ed). Foundation Merieux: Paris, 1993, pp 293-298.
69. Benson J, Chougnet C, Robert-Guroff M, Montefiori D et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol 1998; 72: 4170-4182.
70. Gherardi MM, Ramirez JC, Rodriguez D et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 1999; 162: 6724-6733.
71. Belyakov IM, Moss B, Strober W, Berzofsky JA et al. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA 1999; 96: 4512-4517.
72. Xin KQ, Hamajima K, Sasaki S et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 1999; 17: 858-866.
73. Ramsay AJ, Leong KH, Boyle D, Ruby J, Ramshaw IA. Enhancement of mucosal IgA responses by interleukins 5 and 6 encoded in recombinant vaccine vectors. Reprod Fertil Dev 1994; 6: 389-392.
74. Hamajima K, Sasaki S, Fukushima J et al. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response. Clin Immunol Immunopathol 1998; 88: 205-210.
75. Lu Y, Xin KQ, Hamajima K, Tsuji T. Macrophage inflammatory protein-lalpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin Exp Immunol 1999; 115: 335-341.